MERIT CRO
David Bingaman serves as Chief Development Officer at MERIT CRO since October 2024 and as President & Chief Executive Officer at PanOptica, Inc. from March 2023. Previously, David held the position of Chief Development Officer at Amydis, Inc. and served as Senior Advisor for Development & Innovation Strategy at Ora, Inc. where responsibilities included Clinical Operations, Regulatory Affairs, Preclinical, and CMC. Additional experience includes Vice President and Head of Global Clinical Development at Oculis S.A., and prior roles at PanOptica, Inc. and ALCON RESEARCH LTD. David holds a PhD in Ocular Angiogenesis from Indiana University–Purdue University Indianapolis and extensive training in veterinary medicine from multiple institutions, including a Doctor of Veterinary Medicine from Washington State University.
This person is not in any teams
This person is not in any offices
MERIT CRO
MERIT is an innovative clinical trial endpoint services expert providing reliable and attentive expertise in our therapeutic areas. You can feel confident in our proven track record; we have supported 12 of the top 20 global pharmaceutical companies. Our clients rely on us as a trusted R&D partner. We prioritize a collaborative, partnership-driven approach for all projects with scalable solutions and personalized attention. If you’re looking for a partner that will bring dedication and expertise to your clinical trial, consider MERIT.